Wilfried Roeloffzen

2.8k total citations
23 papers, 259 citations indexed

About

Wilfried Roeloffzen is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Wilfried Roeloffzen has authored 23 papers receiving a total of 259 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hematology, 8 papers in Molecular Biology and 6 papers in Oncology. Recurrent topics in Wilfried Roeloffzen's work include Multiple Myeloma Research and Treatments (5 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (5 papers) and CAR-T cell therapy research (3 papers). Wilfried Roeloffzen is often cited by papers focused on Multiple Myeloma Research and Treatments (5 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (5 papers) and CAR-T cell therapy research (3 papers). Wilfried Roeloffzen collaborates with scholars based in Netherlands, Belgium and United States. Wilfried Roeloffzen's co-authors include Hanneke C. Kluin‐Nelemans, J. Th. M. de Wolf, André B. Mulder, Nic J.G.M. Veeger, Hans Nienhuis, Johan Bijzet, Bouke P. C. Hazenberg, Gea Drost, Jens Kühle and Antje Bischof and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Anesthesia & Analgesia.

In The Last Decade

Wilfried Roeloffzen

18 papers receiving 255 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Wilfried Roeloffzen Netherlands 8 87 65 56 42 37 23 259
Elizabeth A. Jaben United States 10 21 0.2× 67 1.0× 55 1.0× 52 1.2× 25 0.7× 13 319
Kazuyoshi Fukuda Japan 9 31 0.4× 198 3.0× 44 0.8× 37 0.9× 13 0.4× 18 367
Martin Grünewald Germany 11 72 0.8× 212 3.3× 45 0.8× 61 1.5× 30 0.8× 19 384
Hubert Galinat France 11 21 0.2× 112 1.7× 34 0.6× 34 0.8× 61 1.6× 34 277
M‐C. Poon Canada 7 23 0.3× 298 4.6× 22 0.4× 56 1.3× 14 0.4× 8 379
Marcel P.B. Jansen Netherlands 7 19 0.2× 38 0.6× 101 1.8× 36 0.9× 16 0.4× 10 359
Jayne L. Bonan United States 6 47 0.5× 285 4.4× 15 0.3× 71 1.7× 43 1.2× 8 443
Ramona Merki Switzerland 3 13 0.1× 15 0.2× 56 1.0× 161 3.8× 19 0.5× 5 446
Felix Gerhardt Germany 12 27 0.3× 40 0.6× 40 0.7× 296 7.0× 47 1.3× 28 416
Benjamin E. J. Spurgeon United Kingdom 11 9 0.1× 151 2.3× 90 1.6× 59 1.4× 15 0.4× 23 309

Countries citing papers authored by Wilfried Roeloffzen

Since Specialization
Citations

This map shows the geographic impact of Wilfried Roeloffzen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wilfried Roeloffzen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wilfried Roeloffzen more than expected).

Fields of papers citing papers by Wilfried Roeloffzen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wilfried Roeloffzen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wilfried Roeloffzen. The network helps show where Wilfried Roeloffzen may publish in the future.

Co-authorship network of co-authors of Wilfried Roeloffzen

This figure shows the co-authorship network connecting the top 25 collaborators of Wilfried Roeloffzen. A scholar is included among the top collaborators of Wilfried Roeloffzen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wilfried Roeloffzen. Wilfried Roeloffzen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Veeger, Nic J.G.M., et al.. (2025). A systematic review of direct oral anticoagulants for thromboprophylaxis in multiple myeloma. Research and Practice in Thrombosis and Haemostasis. 9(3). 102865–102865. 1 indexed citations
2.
Arnulf, Bertrand, Tessa Kerre, Mounzer Agha, et al.. (2024). Efficacy and safety of ciltacabtagene autoleucel ± lenalidomide maintenance in newly diagnosed multiple myeloma with suboptimal response to frontline autologous stem cell transplant: CARTITUDE-2 cohort D.. Journal of Clinical Oncology. 42(16_suppl). 7505–7505. 2 indexed citations
3.
Delforge, Michel, María‐Victoria Mateos, Kristina Carlson, et al.. (2024). Efficacy of Carvykti in Cartitude-4 Versus Alternative Treatments from Daratumumab Clinical Trials for the Treatment of Patients with Lenalidomide-Refractory Multiple Myeloma. Blood. 144(Supplement 1). 7085–7085. 3 indexed citations
4.
Plattel, Wouter J., Elizabeth de Kort, Alexandra Croockewit, et al.. (2024). Long-Term Follow-up from the Phase 2 ICON Study of Iberdomide Combined with Low-Dose Cyclophosphamide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (IberCd). Blood. 144(Supplement 1). 3371–3371. 1 indexed citations
5.
Bijzet, Johan, Hans Blokzijl, Wilfried Roeloffzen, et al.. (2024). Diagnostic performance of liver stiffness as marker of liver involvement in systemic immunoglobulin light chain (AL) amyloidosis. Annals of Hematology. 104(1). 653–663. 3 indexed citations
6.
7.
8.
9.
Brink, Mirian, et al.. (2021). Prognostic Relevance of Cytogenetic Chromosomal Abnormalities on Outcome Among AL Amyloidosis Patients in the Netherlands. Blood. 138(Supplement 1). 2703–2703. 1 indexed citations
10.
Bijzet, Johan, Wilfried Roeloffzen, Antje Bischof, et al.. (2020). Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis. Amyloid. 28(1). 50–55. 40 indexed citations
11.
Dunnen, Wilfred F.A. den, et al.. (2020). Primary Cauda Equina T-Cell Lymphoblastic Lymphoma. World Neurosurgery. 142. 227–232.
12.
Palladini, Giovanni, Stefan Schönland, Giampaolo Merlini, et al.. (2020). First Glimpse on Real-World Efficacy Outcomes for 2000 Patients with Systemic Light Chain Amyloidosis in Europe: A Retrospective Observational Multicenter Study By the European Myeloma Network. Blood. 136(Supplement 1). 50–51. 13 indexed citations
13.
Roeloffzen, Wilfried, et al.. (2018). Improvement of radiology reporting in a clinical cancer network: impact of an optimised multidisciplinary workflow. European Radiology. 28(10). 4274–4280. 11 indexed citations
14.
Roeloffzen, Wilfried, et al.. (2010). Effects of red blood cells on hemostasis. Transfusion. 50(7). 1536–1544. 34 indexed citations
15.
Roeloffzen, Wilfried, et al.. (2010). Thrombocytopenia affects plasmatic coagulation as measured by thrombelastography. Blood Coagulation & Fibrinolysis. 21(5). 389–397. 29 indexed citations
16.
Roeloffzen, Wilfried, et al.. (2010). Transfused stored platelets have the same haemostatic function as circulating native platelets. Vox Sanguinis. 99(2). 123–130. 12 indexed citations
17.
Roeloffzen, Wilfried, et al.. (2010). In Normal Controls, Both Age and Gender Affect Coagulability as Measured by Thrombelastography. Anesthesia & Analgesia. 110(4). 987–994. 82 indexed citations
18.
Hessels, Jan, et al.. (2003). Assessment of Hypolactasia and Site-Specific Intestinal Permeability by Differential Sugar Absorption of Raffinose, Lactose, Sucrose and Mannitol. Clinical Chemistry and Laboratory Medicine (CCLM). 41(8). 1056–63. 6 indexed citations
19.
Roeloffzen, Wilfried, et al.. (2002). [Acute acalculous cholecystitis: not only in the intensive care department].. PubMed. 146(28). 1305–8.
20.
Roeloffzen, Wilfried. (1998). Fever or a soar throat after start of antithyroidal drugs? A medical emergency. The Netherlands Journal of Medicine. 53(3). 113–117. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elizabeth A. Jaben Breakdown of academic impact, for papers by Kazuyoshi Fukuda Breakdown of academic impact, for papers by Martin Grünewald Breakdown of academic impact, for papers by Hubert Galinat Breakdown of academic impact, for papers by M‐C. Poon Breakdown of academic impact, for papers by Marcel P.B. Jansen Breakdown of academic impact, for papers by Jayne L. Bonan Breakdown of academic impact, for papers by Ramona Merki Breakdown of academic impact, for papers by Felix Gerhardt Breakdown of academic impact, for papers by Benjamin E. J. Spurgeon
Rankless by CCL
2026